Sanofi-aventis (EPA: SAN), the U.K based pharmaceutical, was rated #5 in overall sales and 4th on the list of top R&D spenders in 2006. Sanofi has has trouble over the last year with its drug Acomplia failing to get U.S. Food and Drug Administration approval and its Alzheimer's drug, Xaliproden, failing in late-stage trials but it has several vaccines lined up and of the 48 drugs in late-stage trials, it expects to file for approval on 31 of them by the end of 2010.
Phase III
Rimonabant (Acomplia) - Type 2 diabetes
NV1FGF (fibroblast growth factor) - Critical limb ischemia
Eplivanserin, Volinanserin (5-HT2A antagonists) - sleep maintenance.
Saredutant - Major depressive disorders and general anxiety disorders
Amibegron - Major depressive disorders and general anxiety disorders
Aflibercept (VEGF Trap): Advanced ovarian cancer, prostate cancer, non-small cell lung cancer
S-1 - Second-line treatment for pancreatic cancer
Menactra Toddler - Meningococcal meningitis
Low-dose H5N1 flu vaccine with adjuvant
Dianicline - Smoking cessation
Ilepatril - Blood pressure reduction and long-term cardiovascular and renal protection
[Source: FierceBiotech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 11, 2007 12:43 PM | Permalink to Trackback